Jim Simons Theseus Pharmaceuticals, Inc. Transaction History

Renaissance Technologies LLC

  • $63.1 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024
BUY
$2.12 - $4.18 $308,260 - $607,797
145,406 Added 115.22%
271,600 $1.1 Million
Q3 2023

Nov 14, 2023
BUY
$2.66 - $10.04 $226,084 - $853,339
84,994 Added 206.3%
126,194 $339,000
Q2 2023

Aug 11, 2023
SELL
$7.28 - $11.82 $650,832 - $1.06 Million
-89,400 Reduced 68.45%
41,200 $384,000
Q1 2023

May 12, 2023
BUY
$5.21 - $14.05 $582,478 - $1.57 Million
111,800 Added 594.68%
130,600 $1.16 Million
Q4 2022

Feb 13, 2023
BUY
$4.69 - $8.36 $88,172 - $157,168
18,800 New
18,800 $94,000

Others Institutions Holding THRX

# of Institutions
2
Shares Held
1.03M
Call Options Held
0
Put Options Held
0
View Full List

About Theseus Pharmaceuticals, Inc.

THRX Quotes by TradingView
  • Ticker THRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,713,400
  • Description
  • Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also ...
More about THRX
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email